SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2023 Biotech Charity Contest

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: technetium who wrote (157)10/12/2023 11:57:09 AM
From: technetium2 Recommendations

Recommended By
Aloner
Lance Bredvold

  Read Replies (3) of 233
 
Here we are, the first week of the last quarter. Let’s hope this final quarter is more like the first quarter of the year than the next two. But this first week doesn’t promise any change from the recent overall trends. A decent week to the NASDAQ Composite (+1.6%), adding to a generally good performance, +28% YTD. The NASDAQ biotech index was in the black, barely, while the S&P biotech index dropped -1.1%, for a YTD performance significantly in the red: -13%.

The biggest gainer for individual contest stocks was MRTX (nee MGTA), +37%, probably from the gossip of a possible acquisition by SANOFI, though few details have been announced. The biggest loser was DNTH, -37% of its initial price, perhaps just a correction to the big jump when MGTA performed the reverse merger with DNTH. It has slipped from second to third in the YTD standings, with a still respectable +110% YTD return. INZY was the second worst performer for the week, -32%, adding to the previous week’s slide of -38%, but it is still at the top YTD (+270%). CRVS made it to the 5th position YTD, while MOR was dropped from the top five performers.

The contest portfolios had yet another grim week slicing an additional -$3.2k from their average. Again only a single portfolio was in the black: A.J. MULLEN +$2.3k, owed to their holding of MRTX. They maintained their position of 5th in the YTD standings, still in the red. STEVE LOKNESS, one of the holders of DNTH, dropped -$9.2k, moving it into 3rd position YTD, ERIKOTTO returning to second place. There were no other changes in the top seven YTD rankings.

ALONER, our top YTD portfolio YTD also had a bad week, -$7.6k, another holder of DNTH. They still kept first place YTD position, $9.1k ahead of ERIKOTTO.

Report Time Ranges











From

To

















Recent

9/22/23

10/6/2023

















YTD

12/31/2022









Index Portfolios’ Performance









Symbol

Recent P/L

Recent %

YTD P/L

















^IXIC

$2,025.70

1.6%

$28,327.19

















^NBI

$171.79

0.2%

-$5,987.07

















^SPSIBI

-$959.96

-1.1%

-$12,836.29









Share Performance

Recent Performance

YTD Performance



Top Five



Bottom Five



Top Five



Bottom 5

Symbol

P/L / Initial Price

Symbol

P/L / Initial Price

Symbol

YTD P/L / Initial Price

Symbol

YTD P/L/ Initial Price

MRTX

36.7%

DNTH

-37.4%

INZY

267.6%

APTA.L

-97.7%

JSPR

20.7%

INZY

-32.4%

PRVB

136.5%

AVTX

-97.2%

AEON

10.5%

IMTX

-18.4%

DNTH

109.8%

TCON

-88.8%

LLY

7.7%

MOR

-15.9%

ISEE

86.8%

PTEIQ

-87.2%

VKTX

7.0%

CRIS

-13.5%

CRVS

75.3%

IDIA.SW

-85.1%

Average and Median Portfolio Performance



Recent P/L







YTD P/L







Avg.

Median







Avg

Median







-$3,168.96

-$3,283.34

BLADERUNNER



-$23,034.54

-$27,896.12

ARTHUR RADLEY

Top Seven Portfolio Performances

Top Recent Performers

Top YTD Performers

Contestant (Prev. Rank)

Recent P/L

P/L vs. ^SPSIBI

YTD P/L (Rank)

Contestant (Prev. Rank)

YTD P/L

vs. Top Portfolio

P/L vs. ^SPSIBI

Rec. P/L (Rank)

1 - A.J. MULLEN (4)

$2,364.19

$3,324.15

-$10,698.76 (5)

1 - ALONER (1)

$16,521.04

——

$29,357.33

-$7,552.78 (14)

2 - DEW DILIGENCE (14)

-$824.61

$135.34

-$41,156.50 (13)

2 - ERIKOTTO (3)

$7,393.69

$9,127.35

$20,229.98

-$3,388.80 (9)

3 - TOMATO (8)

-$1,074.21

-$114.26

-$24,178.31 (7)

3 - STEVE LOKNESS (2)

$2,994.18

$13,526.86

$15,830.47

-$9,154.23 (15)

4 - TECHNETIUM (9)

-$1,375.58

-$415.63

-$32,607.52 (10)

4 - RKRW (4)

$1,691.20

$14,829.84

$14,527.48

-$4,152.27 (12)

5 - JACK HARTMANN (1)

-$2,183.81

-$1,223.86

-$30,874.88 (9)

5 - A.J. MULLEN (5)

-$10,698.76

$27,219.80

$2,137.53

$2,364.19 (1)

6 - BMAZ001 (3)

-$2,247.26

-$1,287.30

-$57,572.40 (15)

6 - BLADERUNNER (6)

-$18,028.89

$34,549.93

-$5,192.61

-$3,283.34 (8)

7 - GENEGURU (6)

-$2,494.27

-$1,534.32

-$41,034.96 (12)

7 - TOMATO (7)

-$24,178.31

$40,699.35

-$11,342.02

-$1,074.21 (3)

Top Portfolios’ Contents

Top Recent Performance Portfolio (A.J. MULLEN)

Top YTD Performance Portfolio (ALONER)

Symbol (Rank)

Current Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

Symbol (Rank)

Initial Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

MRTX

12.5%

18.6% | 32.9%

$4,107.81

$4,590.60

6.0%

AFMD

10%

4.3% | -59.9%

-$7,563.03

-$184.54

19.7%

NBIX

12.5%

13.4% | -4.6%

-$576.65

$149.66

8.4%

CDTX

10%

13.0% | 19.7%

$2,491.22

$280.34

6.6%

ONT.L

12.5%

11.4% | -18.9%

-$2,363.32

-$405.00

9.9%

CLSD

10%

8.7% | -19.7%

-$2,488.60

$131.16

9.9%

PACB

12.5%

13.9% | -0.6%

-$76.41

-$336.19

8.0%

CRDF

10%

9.3% | -14.2%

-$1,790.43

-$1,510.15

9.2%

SCLP.L

12.5%

8.4% | -39.8%

-$4,975.72

-$1,029.21

13.3%

CRIS

10%

4.7% | -56.5%

-$7,132.59

-$1,591.62

18.2%

TDOC

12.5%

11.1% | -20.9%

-$2,616.28

$58.14

10.1%

CRVS

10%

18.0% | 66.0%

$8,336.25

$422.10

4.8%

TWST

12.5%

10.7% | -23.9%

-$2,987.19

-$1,123.48

10.5%

KZIA

10%

14.8% | 36.9%

$4,657.41

-$909.76

5.8%

XENE

12.5%

12.6% | -9.7%

-$1,211.01

$459.68

8.9%

DNTH

10%

20.4% | 87.9%

$11,104.80

-$4,235.07

4.2%













MRNA

10%

6.8% | -37.6%

-$4,745.83

$44.77

12.7%













PRVB

10%

0.0% | 136.5%

$13,651.84

$0.00

--

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext